Executive Summary
Generated July 30, 2026
AI Labs
iFLYTEK
Strategic importance is our editorial rating of how central this entity is to the technology landscape we track; confidence reflects how well-sourced and current the underlying evidence is.
0
Chokepoint Score
no direct dependencies recorded in the graph
Headquarters
Hefei, China
Website
Employees
15,000 (2024, approximate)
Founded
1999
Listing
002230 · Shenzhen Stock Exchange
Market Cap
CNY 96.25B
Revenue (TTM)
CNY 27.72B
Price
CNY40.07 (-1.04%)
Market data as of Jul 29, 2026, 11:25 AM · Source: Yahoo Finance (delayed). Not investment advice.
Overview
A major Chinese AI company specializing in speech recognition and natural language processing, one of China's most established AI firms with applications spanning education, healthcare, and government sectors. iFLYTEK reported full-year 2025 revenue of RMB 27.11 billion (~$4.0 billion, up 16.12% year-over-year) and net profit of RMB 839 million (up 49.85%), with its domestically-trained SparkDesk model driving international revenue from Southeast Asia and the Middle East up 275% year-over-year.
Strategic Connections
- US AI Chip Export Controls: iFLYTEK has been on the US Commerce Department's Entity List since 2019, subjecting it to export license requirements for US-origin technology including advanced AI chips.
- AI Accelerators: iFLYTEK's AI voice and language models depend on AI accelerator hardware for training and inference, increasingly sourced domestically under export controls.
- Baidu: iFLYTEK competes with Baidu and other Chinese AI labs in large language models, voice recognition, and enterprise AI services within China's domestic market.
Strategic Risks
- Has faced US export restrictions specifically targeting the company
Future Outlook
- Continued expansion of large language model capabilities built on domestic compute
Sources
2 sources, 75% average source confidence — full citations in the Full Analyst Report.
Generated by InsightNodes — Technology Intelligence Platform. This report reflects sourced, evidence-backed information as of the dates cited above and is not investment advice.
Viewing the Executive Summary — switch to the Full Analyst Report.